NEW YORK, Jan. 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.
Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from GlobalData's July 2013 survey suggests a highly crowded, genericized market.
- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting India Atopic Dermatitis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 112.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 143.2 Symptoms 184 Disease Management 204.1 Diagnosis 204.2 Treatment Overview 224.3 India 284.3.1 Diagnosis 284.3.2 Clinical Practice 305 Competitive Assessment 315.1 Overview 315.2 Strategic Competitor Assessment 325.3 Product Profiles - Major Brands 335.3.1 Protopic (tacrolimus) 335.3.2 Elidel 405.3.3 Cyclosporine (numerous generic names) 465.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 496 Opportunity and Unmet Need 516.1 Overview 516.2 Unmet Needs 526.2.1 A Systemic Drug for Severe Recalcitrant Patients 526.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 546.2.3 A Drug that Effectively Controls Patients' Pruritus 556.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 566.2.5 A Drug that Induces Disease Remission 576.2.6 Improved Quality of Life for Both Patients and their Carers 586.3 Unmet Needs Gap Analysis 586.4 Opportunities 606.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients 606.4.2 Predictive Tests for Patient Stratification 606.4.3 More Therapeutic Options that Address Patients' Pruritus 617 Pipeline Assessment 627.1 Overview 627.2 Promising Drugs in Clinical Development 647.2.1 Phase II Pipeline Products 668 Market Outlook 678.1 Global Drivers and Barriers 678.1.1 Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease 678.1.2 Driver: The underserved severe refractory patient segment presents an untapped market opportunity 688.1.3 Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets 688.1.4 Driver: Atopic dermatitis presents an attractive patient population for drug developers 688.1.5 Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 698.1.6 Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 708.1.7 Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy 708.1.8 Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 708.1.9 Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups 718.1.10 Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy 728.2 India 738.2.1 Forecast 738.2.2 Key Events 758.2.3 Drivers and Barriers 769 Appendix 789.1 Bibliography 789.2 Abbreviations 839.3 Methodology 859.4 Forecasting Methodology 859.4.1 Diagnosed Atopic Dermatitis Patients 869.4.2 Percent Drug-treated Patients 869.4.3 Drugs Included in Each Therapeutic Class 879.4.4 General Pricing Assumptions 879.4.5 Individual Drug Assumptions 889.4.6 Generic Erosion 899.5 Physicians and Specialists Included in this Study 909.6 Primary Research - Prescriber Survey 919.7 About the Authors 929.7.1 Author 929.7.2 Global Head of Healthcare 939.8 About GlobalData 949.9 Disclaimer 94
1.1 List of Tables
Table 1: Symptoms of Atopic Dermatitis 19Table 2: Treatment Guidelines for Atopic Dermatitis 25Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013 27Table 4: Referral Rates to an Indian Dermatologist, Split by Severity and Specialist Type, 2013 28Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in India in 2012 29Table 6: Leading Treatments for Atopic Dermatitis, 2013 33Table 7: Product Profile - Protopic 35Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 36Table 9: Protopic SWOT Analysis, 2013 39Table 10: Product Profile - Elidel 41Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 42Table 12: Elidel SWOT Analysis, 2013 45Table 13: Product Profile - Cyclosporine 47Table 14: Cyclosporine SWOT Analysis, 2013 49Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013 50Table 16: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 52Table 17: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013 59Table 18: Late-Stage Atopic Dermatitis Pipeline, 2013 64Table 19: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013 65Table 20: Phase II and Phase I Atopic Dermatitis Pipeline, 2013 66Table 21: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022 67Table 22: Sales Forecasts ($m) for Atopic Dermatitis in India, 2012-2022 74Table 23: Key Event Impacting Sales for Atopic Dermatitis in India, 2012-2022 75Table 24: Atopic Dermatitis Market in India - Drivers and Barriers, 2012-2022 76Table 25: Physicians Surveyed, By Country 91
1.2 List of Figures
Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin 16Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis 23Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022 64Figure 4: Sales for Atopic Dermatitis in India by Drug Class, 2012-2022 75
To order this report: PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001